Chipiron, a Deeptech startup specializing in Ultra-low MRI, has announced that it has raised $17 million in a Series A funding round led by Blast.
The EIC Fund and Ixcore participated in the round with support from France2030 (SGI) and EIC Accelerator (SGI).European Commission) and bpifrance.
What it does
Chipyron It aims to “democratize” access to MRI by creating lightweight portable machines that can be used in local care centers, private clinics and mobile units.
The French company will use this fund to complete the development of a miniaturized MRI scanner and build the first prototype for hospital deployment.
Clinical trials for the prototype will begin in 2026.
“This funding is a major turning point for Chipiron as it examines both our technical approach and the clinical impact we aim to achieve,” Evan Kerbera, CEO and co-founder of Chipiron, said in a statement.
“Thanks to investor trust, we now have the means to complete the R&D phase and begin clinical research in hospitals next year. Our goal will remain the same from day one to transform MRI accessibility and radically change around the world.”
Market Snapshot
In 2021, Chipilon secured $1.1 million before seed and received $1.1 million of non-diluted funds between 2022 and 2023 to help integrate the early research and development phase.
In 2023, Exor Ventures and Unruly Capital led the $2.7 million seed round.
Other companies in the MRI space include Hyperfine collaborated with Nvidia in March to leverage Nvidia’s AI expertise and rapid computing to enhance Hyperfine’s portable imaging technology, Swoop system.
The Swoop system generates images that display the internal structure of your head. The collaboration between Hyperfine and Nvidia focuses on embedding real-time clinical decision support into portable MRI workflows, as well as the foray into AI-powered image reconstruction and the embedding of real-time clinical decision support.
2024, Springbok Analytics received the FDA 510(K) clearance from Muscleview, an AI-powered technology that analyzes muscle health via MRI.
AI-based technology analyzes MRI data and generates personalized 3D visualizations and metrics of muscle health.
Last year too The Sydney Neuroimaging Analysis Centre has secured government grants to sell AI-driven software to analyze and monitor brain diseases.
The funding helped to expand and accelerate the commercialization of IQ-Solutions’ AI-enabled medical imaging software, which provides quantitative analysis of brain structures from MRI scans.
It enables monitoring and management of brain diseases, including multiple sclerosis and dementia.
